1-甲基-1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮 | 89418-11-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 中文名称: 1-甲基-1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮
• 英文名称: 1-methyl-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one
• 英文别名: 1-Methyl-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one；1-methyl-2H-pyrazolo[3,4-d]pyrimidin-3-one
• CAS: 89418-11-1
• 化学式: C₆H₆N₄O
• 分子量: 150.14
• InChiKey: GOGWIEYQVGBUEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  58.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-甲基-1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮 在 caesium carbonate 、 N,N-二异丙基乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.5h， 生成 2-((7-((R)-3-cyclohexyl-2-methylpropanoyl)-10-hydroxy-7-azaspiro[4.5]decan-10-yl)methyl)-1-methyl-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one
  参考文献：
  名称：

  WO2020115501A5

  摘要：

  公开号：

  WO2020115501A5

文献信息

• Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
  申请人：CS PHARMATECH LIMITED

  公开号：US10435388B2

  公开（公告）日：2019-10-08

  The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.

  本发明提供了式(I)化合物或其亚属结构或种类或其药学上可接受的盐、酯、溶液剂和/或原药，以及用于治疗或改善异常细胞增殖性疾病（如癌症）的方法和组合物，其中A、R2、R3、R10、E1、E2、E3、Y和Z如本文所定义。
• CHEMICAL COMPOUNDS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1432714B1

  公开（公告）日：2008-08-06
• 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)
  申请人：Almac Discovery Limited

  公开号：EP3746432B1

  公开（公告）日：2022-12-14
• SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE
  申请人：CS PHARMATECH LIMITED

  公开号：US20190023689A1

  公开（公告）日：2019-01-24

  The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R 2 , R 3 , R 10 , E 1 , E 2 , E 3 , Y, and Z are as defined herein.
• PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)
  申请人：ALMAC DISCOVERY LIMITED

  公开号：US20220033397A1

  公开（公告）日：2022-02-03

  Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those a compounds for use in methods of treating muscular atrophy.